Most linked-to pages

Showing below up to 50 results in range #1 to #50.

1. Not specified‏‎ (78 links)
2. 3‏‎ (49 links)
3. 4‏‎ (36 links)
4. 2‏‎ (35 links)
5. 1‏‎ (17 links)
6. Not rated‏‎ (9 links)
7. Property:Has Toxicity Level‏‎ (8 links)
8. Property:Has Usefulness Rating‏‎ (8 links)
9. Property:Has treatment name‏‎ (7 links)
10. 2.5‏‎ (6 links)
11. Not applicable‏‎ (4 links)
12. Property:Has Toxicity Explanation‏‎ (4 links)
13. 23 months median survival, with 47% at 2 years‏‎ (3 links)
14. 3.5‏‎ (3 links)
15. 3 (awaiting research)‏‎ (3 links)
16. 3 - Under investigation‏‎ (3 links)
17. 5‏‎ (3 links)
18. 6.1 months for all patients, 5.9 months for EGFR amplified patients‏‎ (3 links)
19. AVAglio trial: 16.8 months; RTOG trial: 15.7 months‏‎ (3 links)
20. BCNU (Carmustine) and Gliadel (Carmustine Wafers)‏‎ (3 links)
21. Bevacizumab (Avastin)‏‎ (3 links)
22. CBD‏‎ (3 links)
23. CBD (Cannabidiol)‏‎ (3 links)
24. CCNU (Lomustine)‏‎ (3 links)
25. Cannabigerol (CBG)‏‎ (3 links)
26. Cannabis‏‎ (3 links)
27. Cannabis and Cannabis-derived Products (e.g., Sativex)‏‎ (3 links)
28. Celebrex (Celecoxib) and Other NSAIDs‏‎ (3 links)
29. Chloroquine‏‎ (3 links)
30. Chloroquine and Hydroxychloroquine‏‎ (3 links)
31. Combination of Repurposed Drugs plus Temodar‏‎ (3 links)
32. Comparable to standard TMZ treatments, but timing affects management of side effects.‏‎ (3 links)
33. Disulfiram (Antabuse)‏‎ (3 links)
34. Ellagic Acid‏‎ (3 links)
35. Fish Oil (Omega-3 Fatty Acids: EPA and DHA)‏‎ (3 links)
36. Fish oil‏‎ (3 links)
37. Gamma-Linolenic Acid (GLA)‏‎ (3 links)
38. Garlic (Allium sativum)‏‎ (3 links)
39. Gliadel: 13.9 months median survival; Combination with TMZ: Median survival ranges from 17 to 20.7 months‏‎ (3 links)
40. ICT-107 has demonstrated potential in extending progression-free and overall survival in GBM patients, especially in specific subgroups. Its ability to target multiple tumor-associated antigens may offer a broader immunogenic response.‏‎ (3 links)
41. Isotretinoin (Accutane)‏‎ (3 links)
42. Keppra‏‎ (3 links)
43. Keppra (Levetiracetam)‏‎ (3 links)
44. MN-166 (Ibudilast)‏‎ (3 links)
45. Methadone (D,L-methadone)‏‎ (3 links)
46. Not applicable; studies focusing on PFS-6 as a primary endpoint‏‎ (3 links)
47. Not reached at a median follow-up of 5.8 months‏‎ (3 links)
48. Not specified in the provided text‏‎ (3 links)
49. PFS-6 value was 53% in a restricted patient population with overexpression of PDGFR‏‎ (3 links)
50. PSK (Polysaccharide Krestin) and other polysaccharides‏‎ (3 links)